Zacks: Brokerages Expect Aduro BioTech Inc (ADRO) to Announce -$0.36 Earnings Per Share
Brokerages expect that Aduro BioTech Inc (NASDAQ:ADRO) will post earnings of ($0.36) per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Aduro BioTech’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.46). Aduro BioTech reported earnings of ($0.44) per share during the same quarter last year, which indicates a positive year over year growth rate of 18.2%. The company is scheduled to issue its next quarterly earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Aduro BioTech will report full-year earnings of ($1.28) per share for the current financial year, with EPS estimates ranging from ($1.39) to ($1.22). For the next year, analysts expect that the firm will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.66) to ($0.78). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Aduro BioTech.
A number of equities research analysts have commented on the company. ValuEngine lowered Aduro BioTech from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. BidaskClub lowered Aduro BioTech from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 3rd. Canaccord Genuity set a $30.00 price objective on Aduro BioTech and gave the stock a “buy” rating in a research report on Thursday, December 14th. HC Wainwright set a $18.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Wednesday, November 1st. Finally, Oppenheimer reduced their price target on Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating for the company in a report on Wednesday, December 13th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.71.
Institutional investors have recently made changes to their positions in the company. Harvard Management Co. Inc. bought a new position in shares of Aduro BioTech in the 3rd quarter valued at approximately $69,418,000. Vanguard Group Inc. raised its stake in shares of Aduro BioTech by 5.4% in the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock valued at $28,637,000 after acquiring an additional 129,079 shares in the last quarter. State Street Corp raised its stake in shares of Aduro BioTech by 8.3% in the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock valued at $7,808,000 after acquiring an additional 52,597 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of Aduro BioTech by 30.8% in the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock valued at $5,891,000 after acquiring an additional 130,390 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Aduro BioTech by 15.1% in the 2nd quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock valued at $5,166,000 after acquiring an additional 59,490 shares in the last quarter. Institutional investors and hedge funds own 45.14% of the company’s stock.
Shares of Aduro BioTech (NASDAQ:ADRO) traded up $0.05 during midday trading on Monday, reaching $6.10. The company’s stock had a trading volume of 886,973 shares, compared to its average volume of 538,847. Aduro BioTech has a 12-month low of $5.82 and a 12-month high of $14.05. The firm has a market cap of $467.69, a price-to-earnings ratio of -4.49 and a beta of 3.01.
COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Expect Aduro BioTech Inc (ADRO) to Announce -$0.36 Earnings Per Share” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/10/zacks-brokerages-expect-aduro-biotech-inc-adro-to-announce-0-36-earnings-per-share.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.